title: Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells.
abstract: Platinum-based concurrent chemoradiotherapy is considered a standard treatment approach for locoregionally advanced nasopharyngeal carcinoma. However, only a minority of patients benefit from this treatment regimen compared with radiotherapy alone. Identification of a set of molecular markers predicting sensitivity of platinum-based chemotherapy may contribute to personalized treatment of patients with nasopharyngeal carcinoma for better clinical outcome with less toxicity. Previously, we generated a cisplatin-sensitive nasopharyngeal carcinoma cell line, S16, by clonal selection from CNE-2 cells and found that eIF3a is upregulated and contributes to cisplatin sensitivity by downregulating the synthesis of nucleotide excision repair proteins. In this study, we conducted a gene expression profiling analysis and found three other genes, asparagine synthetase (ASNS), choriogonadotropin α subunit (CGA), and matrix metalloproteinase 19 (MMP19), that are upregulated in the cisplatin-sensitive S16 cells compared with the CNE-2 cells. However, only ASNS and MMP19, but not CGA, contributes to cisplatin sensitivity by potentiating cisplatin-induced DNA damage and apoptosis. Thus, ASNS and MMP19, along with eIF3a, are the sensitivity factors for cisplatin treatment and may serve as potential candidate molecular markers for predicting cisplatin sensitivity of advanced nasopharyngeal carcinoma.
authors: Corresponding Authors: Jian-Ting Zhang, Indiana University School of Medicine, 980 W. Walnut St., Walther Hall-C510, Indianapolis, IN 46202-5424. jianzhan@iupui.edu.
authors: Ran-Yi
authors: RY
authors: Liu
authors: Zizheng
authors: Z
authors: Dong
authors: Jianguo
authors: J
authors: Liu
authors: Ling
authors: L
authors: Zhou
authors: Wenlin
authors: W
authors: Huang
authors: Sok Kean
authors: SK
authors: Khoo
authors: Zhongfa
authors: Z
authors: Zhang
authors: David
authors: D
authors: Petillo
authors: Bin Tean
authors: BT
authors: Teh
authors: Chao-Nan
authors: CN
authors: Qian
authors: Jian-Ting
authors: JT
authors: Zhang
mesh_terms: D001217:Aspartate-Ammonia Ligase / Q000096:biosynthesis* / Q000235:genetics; D054316:Biomarkers, Pharmacological; D002277:Carcinoma; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D053505:Matrix Metalloproteinases, Secreted / Q000096:biosynthesis* / Q000235:genetics; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D054316:Biomarkers, Pharmacological; D053505:Matrix Metalloproteinases, Secreted; C108362:matrix metalloproteinase 19; D001217:Aspartate-Ammonia Ligase; D002945:Cisplatin
references: Oncogene. 2003 Oct 20;22(47):7265-79
references: 14576837
references: Exp Cell Res. 2009 Jul 1;315(11):1889-94
references: 19327350
references: Cancer. 2011 Jan 15;117(2):238-49
references: 20824725
references: Cell. 2010 Apr 2;141(1):52-67
references: 20371345
references: Cancer Metastasis Rev. 2007 Mar;26(1):71-83
references: 17318448
references: Crit Rev Oncol Hematol. 2002 Jun;42(3):317-25
references: 12050023
references: Int J Biol Markers. 2007 Oct-Dec;22(4):265-73
references: 18161657
references: Int J Cancer. 2011 Oct 15;129(8):1826-37
references: 21165953
references: Chin J Cancer. 2011 Feb;30(2):114-9
references: 21272443
references: Chin J Cancer. 2010 May;29(5):517-26
references: 20426903
references: Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):47-56
references: 16377415
references: Cancer Res. 2003 Jan 1;63(1):256-62
references: 12517806
references: J Biol Chem. 1997 Feb 14;272(7):4281-6
references: 9020145
references: Int J Oncol. 2004 Apr;24(4):773-95
references: 15010814
references: Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9
references: 11493696
references: Mol Cancer Ther. 2006 Nov;5(11):2613-23
references: 17088436
references: J Neuropathol Exp Neurol. 2010 Mar;69(3):215-23
references: 20142769
references: J Cell Physiol. 2008 Aug;216(2):480-5
references: 18286480
references: Int J Oncol. 2002 Dec;21(6):1197-204
references: 12429968
references: Mol Pharmacol. 2010 Jun;77(6):887-94
references: 20159940
references: Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
references: 17318226
references: Int J Nanomedicine. 2006;1(3):241-54
references: 17717965
references: Cancer Res. 2007 Apr 1;67(7):3345-55
references: 17409444
references: Cancer Res. 1993 Sep 1;53(17):3976-85
references: 8358726
references: Int J Cancer. 1983 May 15;31(5):587-90
references: 6852976
references: Chin J Cancer. 2012 Apr;31(4):185-96
references: 22313595
references: Nat Rev Cancer. 2007 Aug;7(8):573-84
references: 17625587
references: Nature. 2008 Feb 28;451(7182):1111-5
references: 18264088
references: Nat Rev Drug Discov. 2005 Apr;4(4):307-20
references: 15789122
references: Gene. 2000 Jul 11;252(1-2):27-37
references: 10903435
references: Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113
references: 9768345
references: J Biol Chem. 2002 Nov 15;277(46):44268-77
references: 12235150
references: Mod Pathol. 2010 Apr;23(4):511-21
references: 20098411
references: PLoS One. 2009 May 24;4(5):e5676
references: 19479068
references: Mol Cancer Ther. 2008 Feb;7(2):263-70
references: 18281512
references: Nature. 2008 Feb 28;451(7182):1116-20
references: 18264087
references: Oral Oncol. 2009 Oct;45(10):866-71
references: 19442568
references: Clin Cancer Res. 2008 Mar 1;14(5):1291-5
references: 18316546
references: Adv Enzymol Relat Areas Mol Biol. 1998;72:145-98
references: 9559053
references: Oncogene. 2011 Dec 1;30(48):4814-23
references: 21625209
references: Eur J Cancer. 1998 Sep;34(10):1522-34
references: 9893623
references: Chin J Cancer. 2010 May;29(5):551-5
references: 20426907
references: J Biol Chem. 1998 Mar 6;273(10):5858-68
references: 9488723
references: Nat Med. 2008 May;14(5):495-6
references: 18463659
references: Cancer Treat Rev. 2007 Feb;33(1):9-23
references: 17084534